Nanobiotix News

17,45 +6,34% +1,04 €
09:15 Uhr Frankfurt | Orderbuch | Mehr Kurse »
ISIN: FR0011341205
Typ: Aktie

Nanobiotix News

Do Nanobiotix Revenue for the 2nd Quarter of 2018 Businesswire
21.06.18 NANOBIOTIX Announces Positive Phase II/III Topline Data in Soft Tissue Sarcoma with NBTXR3 Businesswire
21.06.18 NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 GlobeNewswire
06.06.18 Nanobiotix’ Management Statement on Recent Share Price Variation Businesswire
06.06.18 NANOBIOTIX' Management statement on recent share price variation GlobeNewswire
15.05.18 Nanobiotix Revenue for the 1st Quarter of 2018 Businesswire
03.05.18 Nanobiotix Partners with Weill Cornell Medicine on Pre-​Clinical Studies to Evaluate the Impact of NBTXR3 on cGAS-​STING Pathway in Mammary Cancers Businesswire
03.05.18 Nanobiotix partners with Weill Cornell Medicine on pre-​clinical studies to evaluate the impact of NBTXR3 on cGAS-​STING pathway in mammary cancers GlobeNewswire
26.04.18 NANOBIOTIX Selected to Enter Euronext’s Tech 40 Label Businesswire
17.04.18 AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-​STING pathway GlobeNewswire
30.03.18 NANOBIOTIX : Nanobiotix 2017 Annual Results GlobeNewswire
22.01.18 NANOBIOTIX presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting GlobeNewswire
11.01.18 NANOBIOTIX partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers GlobeNewswire
26.12.17 NANOBIOTIX : 2017 review and 2018 expected milestones GlobeNewswire
26.12.17 NANOBIOTIX : FDA approves Nanobiotix's first Immuno-​Oncology trial GlobeNewswire
13.11.17 NANOBIOTIX presented new clinical and pre-​clinical data confirming NBTXR3's significant potential role in Immuno-​Oncology at SITC Annual Meeting GlobeNewswire
09.11.17 NANOBIOTIX provides update on the global development of its lead product NBTXR3 GlobeNewswire
23.10.17 NANOBIOTIX completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma GlobeNewswire
28.09.17 NANOBIOTIX plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S. GlobeNewswire
31.08.17 NANOBIOTIX half year results for the six months ended 30 June 2017 GlobeNewswire
15.06.17 NANOBIOTIX : new translational data presented at ASTRO, NCI AND SITC'S Immunotherapy Workshop GlobeNewswire
05.06.17 NANOBIOTIX : promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology's Annual Meeting GlobeNewswire
18.05.17 NANOBIOTIX announces first positive Human data showing that NBTXR3 could become a backbone in Immuno-​Oncology GlobeNewswire
28.04.17 NANOBIOTIX : 2016 Annual Results GlobeNewswire
04.04.17 NANOBIOTIX : Nanobiotix expands its clinical development in Head and Neck cancer and Immuno-​Oncology ; new clinical data to be presented at ASCO GlobeNewswire
23.03.17 NANOBIOTIX: the Independent Data Monitoring Committee recommends the continuation of the ongoing phase II/III trial of NBTXR3 in Soft Tissue Sarcoma GlobeNewswire
07.03.17 NANOBIOTIX : Nanobiotix to present preclinical data on nanoparticle radioenhancer NBTXR3 at the AACR Annual Meeting 2017 GlobeNewswire
07.02.17 NANOBIOTIX appoints senior executive from pharmaceutical industry, as Chief Operating Officer GlobeNewswire
31.01.17 NANOBIOTIX : 2016 review and 2017 anticipated milestones GlobeNewswire
14.12.16 NANOBIOTIX reports positive Phase I/II preliminary data on feasibility and safety of NBTXR3 in liver cancers trial GlobeNewswire
28.11.16 NANOBIOTIX Provides Update on Global Development of Lead Product NBTXR3 GlobeNewswire
14.11.16 NANOBIOTIX presents NBTXR3 preclinical data demonstrating its potential usage as in situ vaccine for cancer at the Society for Immunotherapy of Cancer Annual Meeting GlobeNewswire
20.10.16 Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia GlobeNewswire
20.10.16 Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia GlobeNewswire
20.10.16 Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia GlobeNewswire
03.10.16 NANOBIOTIX Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations GlobeNewswire
19.09.16 Bpifrance grants Nanobiotix a 2M€ interest-​free loan to support final development stage of lead product, NBTXR3 GlobeNewswire
13.09.16 Nanobiotix announces submission for first market approval of lead product NBTXR3 in Europe GlobeNewswire
06.07.16 Nanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer GlobeNewswire
31.05.16 Nanobiotix establishes promising preclinical proof-​of-concept in Immuno Oncology GlobeNewswire
29.04.16 Nanobiotix: 2015 Annual Results GlobeNewswire
04.01.16 NANOBIOTIX : FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostate cancer GlobeNewswire
13.11.15 Nanobiotix's Soft Tissue Sarcoma pivotal trial expands dynamically as planned: already 7 countries and 29 sites opened GlobeNewswire
01.07.15 NANOBIOTIX :starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3 GlobeNewswire
10.06.15 NANOBIOTIX :reports positive preliminary results in Head and Neck cancer Phase I/II clinical trial with NBTXR3 GlobeNewswire
14.04.15 NANOBIOTIX : 2014 ANNUAL RESULTS GlobeNewswire
19.02.15 Professor Robert Langer joins Nanobiotix as Scientific Advisor GlobeNewswire
16.10.14 Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe GlobeNewswire
08.10.14 PharmaEngine will join Nanobiotix' pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-​Pacific GlobeNewswire




09:50 Uhr
DAX-Check: Putin trifft Trump - Das könnte für Bewegung sorgen